Latest news

Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer

Sanvar® (Debio 8609) for esophageal variceal bleeding – Debiopharm submits response to the FDA

Japanese Cancer Association and Debiopharm Honour Japanese Research – Professors Ichijo and Mano receive 2008 JCA-Mauvernay Award

Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients – Debiopharm Starts Tablet Formulation Bridging Study under IN

Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients

Debiopharm investit pour les médicaments innovants de demain – Inauguration de Campus “après-demain”, son site de développement et de production

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment

Doctor Manel Esteller Receives the Debiopharm Life Sciences Award For his Outstanding Research in Epigenetic Oncology